Bank of America
FDMT icon

Bank of America’s 4D Molecular Therapeutics FDMT Stock Holding History

Bank of America’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,000
Closed -$11.1K – 8429
2025
Q2 		$11.1K Buy
+3,000
New +$10.5K ﹤0.01% 7174

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Bank of America's FDMT Position: Q1 2026 in Review

Bank of America increased its 4D Molecular Therapeutics (FDMT) stake by 17% in Q1 2026, buying an estimated $1.23M and bringing the position to 974,173 shares worth $9.07M. The position accounts for ﹤0.01% of the portfolio, ranked #3039.

Bank of America first reported a position in FDMT in Q4 2020 and has held it in 22 quarters since. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Bank of America held 974,173 shares of 4D Molecular Therapeutics worth $9.07M as of Q1 2026.
  • Bank of America bought 141,582 4D Molecular Therapeutics shares in Q1 2026, an estimated $1.23M.
  • 4D Molecular Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #3039 holding.
  • Bank of America first reported a position in 4D Molecular Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.